Novartis Readies Sales Force For Galvus Ramp-Up In China; Abbott Improves Margin For Nutritionals – Emerging Market Earnings Roundup (Part 1)
This article was originally published in PharmAsia News
Executive Summary
Novartis calls 2012 its most challenging year. Abbott projects foreign exchange swings to lead to overall flat revenue growth. Yet both companies plan to offset losses through growth in emerging markets.
You may also be interested in...
Follow The CEO? Abbott Chief Chooses Diversified Products, Emerging Markets Over Rx Drugs As Company Splits In Two
Abbott Laboratories CEO Miles White has complained for a long time that U.S. investors don't understand the growth opportunity of emerging markets. Now White finally has a chance to put his money where his mouth is, choosing to lead a diversified medical products company rather than an innovative pharmaceutical company that will carry a different name, following a decision to split Abbott into two companies
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.